User profiles for Noemi Reguart

Noemi Reguart

Hospital Clinic Barcelona
Verified email at clinic.ub.es
Cited by 20651

Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer

…, V Calvo, A Insa, S Ponce, N Reguart… - … England Journal of …, 2023 - Mass Medical Soc
Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma

A Prat, A Navarro, L Paré, N Reguart, P Galván… - Cancer research, 2017 - AACR
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a
variety of solid tumors, but most patients exhibit partial or complete resistance to treatment …

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …

…, E Dansin, J De Castro, M Milella, N Reguart… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial

…, E Carcereny, E Felip, I Bover, A Insa, N Reguart… - JAMA …, 2015 - jamanetwork.com
Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …

[HTML][HTML] Screening for epidermal growth factor receptor mutations in lung cancer

…, MA Moreno, S Catot, C Rolfo, N Reguart… - … England Journal of …, 2009 - Mass Medical Soc
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm …

…, P Bidoli, A Favaretto, P Froesch, N Reguart… - The Lancet …, 2017 - thelancet.com
Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …

PD-L1 expression testing in non-small cell lung cancer

…, N Vilarińo, R Reyes, N Reguart - … Advances in Medical …, 2018 - journals.sagepub.com
In recent years, immunotherapy has revolutionized and changed the standard of care in
patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, …

[HTML][HTML] Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

J Wolf, T Seto, JY Han, N Reguart… - … England Journal of …, 2020 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), MET exon 14
skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a …

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts

…, J Ramírez, S Moran, E Vidal, N Reguart… - …, 2015 - academic.oup.com
Epigenetic changes through altered DNA methylation have been implicated in critical aspects
of tumor progression, and have been extensively studied in a variety of cancer types. In …

[PDF][PDF] Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

…, E Caudler, Y Lo, F Baribaud, I Mikami, N Reguart… - Cancer cell, 2006 - cell.com
We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of
heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small …